Drug · CHEMBL38

TRETINOIN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. TRETINOIN. Drugs and targets, record CHEMBL38. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL38

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: TRETINOIN; ChEMBL
ChEMBL ID: CHEMBL38; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Acticin, Altreno, Atralin, Avita, Renova, Retin-a, Retin-a micro, Retin-a-micro, Tretin-x, Tretinoin component of solage, Tretinoin component of tri-luma, Tretinoin component of twyneo, Tretinoin component of veltin, Tretinoin component of ziana, Vesanoid; ChEMBL
Other names: Aberel, All-trans retinoic acid, All-trans-retinoic acid, Eudyna, Kerlocal, NSC-122758, Oristar rna, Retin a, Retinoic acid, Tretinoina, Tretinoine; ChEMBL
DrugBank: DB00755; DrugBank
InChIKey: SHGAZHPCJJPHSC-YCNIQYBTSA-N; ChEMBL
Open Targets' highest stage: Approval, for 5 of its 71 diseases, from ATC, DailyMed and TTD; Open Targets

Targets3

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
RARA	Retinoic acid receptor	Retinoic acid receptor agonist	AGONIST	https://conductscience.org/library/genes/5914
RARB	Retinoic acid receptor	Retinoic acid receptor agonist	AGONIST	https://conductscience.org/library/genes/5915
RARG	Retinoic acid receptor	Retinoic acid receptor agonist	AGONIST	https://conductscience.org/library/genes/5916

Source ChEMBL

Diseases71

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
acne	Approval	ATC, DailyMed and TTD	88	41	https://conductscience.org/library/drugs?q=MONDO_0011438
acute promyelocytic leukemia	Approval	DailyMed	40	37	https://conductscience.org/library/drugs?q=MONDO_0012883
acute myeloid leukemia	Phase 3	ClinicalTrials.gov	36	36	https://conductscience.org/library/drugs?q=MONDO_0018874
myelodysplastic syndrome	Phase 3	ClinicalTrials.gov	17	17	https://conductscience.org/library/drugs?q=MONDO_0018881
freckles	Approval	DailyMed	12	11	https://conductscience.org/library/drugs?q=EFO_0003963
autoimmune thrombocytopenic purpura	Phase 3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0008558
plasma cell myeloma	Phase 2	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0009693
non-small cell lung carcinoma	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0005233
melanoma	Phase 2	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005105
breast cancer	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0007254

1 to 10 of 71Source Open Targets

See all 71 diseases

Trials245

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 4 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00689117	A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel	Phase 3	1,649	2010-12-02	tretinoin	Its name	ClinicalTrials.gov
NCT01243450	Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo	Phase 3	958	2014-11-18	tretinoin	Its name	ClinicalTrials.gov
NCT02932306	Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris	Phase 3	820	2020-01-03	tretinoin	Its name	ClinicalTrials.gov
NCT02965456	Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris	Phase 3	820	2019-12-18	tretinoin	Its name	ClinicalTrials.gov
NCT02249767	Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel	Phase 3	574	2020-01-13	tretinoin	Its name	ClinicalTrials.gov
NCT01135069	Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo	Phase 3	480	2014-10-16	tretinoin	Its name	ClinicalTrials.gov
NCT00907257	A Study of Different Use Regimens Using Two Acne Treatments	Phase 4	247	2011-01-21	tretinoin	Its name	ClinicalTrials.gov
NCT00835198	Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris	Phase 4	163	2011-10-31	tretinoin	Its name	ClinicalTrials.gov
NCT00952523	Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face	Phase 4	162	2010-04-09	tretinoin	Its name	ClinicalTrials.gov
NCT02339740	Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia	Phase 3	158	2021-12-16	tretinoin	Its name	ClinicalTrials.gov

1 to 10 of 245

See all 245 trials

Comparisons in its trials36

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
IDP-121 Lotion vs IDP-121 Vehicle Lotion: deaths from any cause	0 of 389	0 of 398	787	NCT02965456	Trial comparisons
IDP-121 Lotion vs IDP-121 Vehicle Lotion: serious adverse events	2 of 389	2 of 398	787	NCT02965456	Trial comparisons
IDP-121 Lotion vs IDP-121 Vehicle Lotion: deaths from any cause	0 of 378	0 of 385	763	NCT02932306	Trial comparisons
IDP-121 Lotion vs IDP-121 Vehicle Lotion: serious adverse events	5 of 378	2 of 385	763	NCT02932306	Trial comparisons
Tretinoin Facial Gel vs Adapalene-Benzoyl Peroxide Facial Gel: serious adverse events	0 of 162	0 of 162	324	NCT00952523	Trial comparisons
Same Time of Day vs Different Times of Day: serious adverse events	3 of 123	0 of 124	247	NCT00907257	Trial comparisons
Tretinoin Gel 0.025% vs Dapsone Gel 5% and Tretinoin Gel 0.025%: serious adverse events	0 of 82	0 of 81	163	NCT00835198	Trial comparisons
Standard Risk vs High Risk: deaths from any cause	1 of 101	0 of 57	158	NCT02339740	Trial comparisons
Standard Risk vs High Risk: serious adverse events	3 of 101	2 of 57	158	NCT02339740	Trial comparisons
Intense Pulsed Light (IPL) / Tri-Luma® Cream vs Intense Pulsed Light (IPL) / Inactive Control Cream: Number of Participants With Tolerability Assessments Resulting in Adverse Events	1 of 56	0 of 56	112	NCT00669071	Trial comparisons

1 to 10 of 36

See all 36 comparisons in its trials

Papers from its trials117

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40825164	RESULT	1	PubMed
39775043	RESULT	1	PubMed
39369111	RESULT	1	PubMed
38896402	RESULT	1	PubMed
38192412	RESULT	1	PubMed
37620285	RESULT	1	PubMed
35357753	RESULT	1	PubMed
33849384	RESULT	1	PubMed
32649234	RESULT	1	PubMed
31502392	RESULT	1	PubMed

1 to 10 of 117

See all 117 papers from its trials

Tests in its trials1

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome
Verbal Learning	1	0

Source ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL38

GET https://conductscience.org/api/drugs/v1/CHEMBL38/diseases?page=2

API reference For AI assistants